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1. Introduction
The use of gold nanoparticles (AuNPs) in biomedical applica-
tions has grown to become one of the largest research areas 
in nanoscience.[1–4] Their strong plasmonic response and high 
photothermal efficiency have made them particularly appealing 
as photothermal conversion agents in the therapy and imaging 
Gold nanorods (AuNRs) have attracted a great deal of attention due to their 
potential for use in a wide range of biomedical applications. However, their 
production typically requires the use of the relatively toxic cationic surfactant 
cetyltrimethylammonium bromide (CTAB) leading to continued demand for 
protocols to detoxify them for in vivo applications. In this study, a robust and 
facile protocol for the displacement of CTAB from the surface of AuNRs using 
phospholipids is presented. After the displacement, CTAB is not detectable 
by NMR spectroscopy, surface-enhanced Raman spectroscopy, or using pH-
dependent ζ-potential measurements. The phospholipid functionalized  
AuNRs demonstrated superior stability and biocompatibility (IC50 > 200 µg mL−1)  
compared to both CTAB and polyelectrolyte functionalized AuNRs and are 
well tolerated in vivo. Furthermore, they have high near-infrared (NIR) absorb-
ance and produce large amounts of heat under NIR illumination, hence such 
particles are well suited for plasmonic medical applications.
of cancer[5–7] and for thermally triggered 
drug release in the treatment of patho-
gens.[8] AuNPs can be synthesized such 
that they possess strong absorbance within 
the “near-infrared biological window.” 
Within this range of wavelengths, light 
can penetrate biological tissue by several 
centimeters. This enables them to be used 
as in vivo nano-heaters to thermally ablate 
cancerous tissue with minimal heat gener-
ation in the intermediate tissue along the 
light path.[9,10]
In this role, gold nanorods (AuNRs) 
are exceptionally well suited, offering 
a strong narrow absorbance peak, tun-
able throughout red and near-infrared 
(NIR) wavelengths. While other AuNP 
morphologies, including nanoplates,[11] 
nanotubes,[12,13] and nanoshells[14] offer 
absorbance peaks in the NIR, AuNRs have the highest absorb-
ance cross-sections (σabs) per unit mass of any AuNP, with an 
σabs typically an order of magnitude higher than that seen for 
Au nanoshells containing an equivalent mass of Au.[15] This is 
particularly advantageous in photothermal applications as the 
power of heat generation of an AuNP is proportional to its σabs 
at the illumination wavelength.[5]
AuNR synthesis protocols remain dependent on the use of the 
surfactant cetyltrimethylammonium bromide (CTAB) as a shape-
directing agent.[16–18] This is problematic as CTAB is a highly 
toxic amphiphile. It is capable of disrupting negatively charged 
cell membranes and quenching the activity of adenosine triphos-
phate (ATP) synthase, leading to rapid cell death.[19,20] CTAB 
forms a bilayer structure on the surface of AuNRs and exists 
in dynamic equilibrium with the local environment, requiring 
toxic concentrations of free CTAB in the surrounding medium 
to maintain colloidal stability.[21,22] Considerable research output 
has been focused on either the passivation or replacement of this 
layer to render such particles safe for use in biomedical appli-
cations. Additionally, CTAB is a very poor stabilizing agent and 
fails to maintain the stability of particles in most biologically 
relevant buffers.[23] The human body presents a particularly chal-
lenging environment for the maintenance of colloidal stability, 
with human plasma exhibiting a relatively high salinity of around 
300 mOsm L−1 and contains a wide variety of biomolecules 
which will bind non-specifically to NPs, often undermining any 
specific surface functionalization bestowed on the particle. This 
is extremely problematic for most targeting strategies, as the 
© 2021 The Authors. Small published by Wiley-VCH GmbH. This is an 
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resulting protein corona is typically 10–100 nm thick,[24] above the 
size of most targeting ligands (i.e., antibodies are ≈10–15  nm), 
leading to the corona completely obscuring such molecules.
Multiple functionalization strategies have been developed 
to combat these issues. The most common can be broadly 
grouped into two main categories: thiol displacement and sur-
face passivation. Thiol displacement approaches rely on the high 
binding affinity between thiols and Au, leading to the competi-
tive replacement of CTAB by molecules such as alkanethiols[25] 
or poly(ethylene glycol)-thiols (PEG-thiols).[26,27] Surface passiva-
tion focuses on encapsulating the CTAB in a low permeability 
polymer layer, such as poly(styrene sulfonate) (PSS)[12,28,29] or 
poly(acrylic acid);[30,31] or a layer of amorphous silica[32–37,47] 
thereby containing the CTAB and improving the biocompatibility.
An alternative approach to these is direct surfactant exchange. 
This method has received some attention in the literature, 
although remains relatively uncommon.[38–44] These techniques 
generally consist of dispersing a pellet of CTAB-functionalized 
AuNRs in a solution containing a large excess of the desired 
surfactant and then providing energy to encourage exchange 
between the solution and the particle surface in the form of 
heat or sonication. These techniques have been reported for 
several molecules including phospholipids[38–42] and oleate.[43,44] 
Phospholipids offer many benefits resulting from the highly 
tailorable properties of lipid membranes; including, low non-
specific binding, high biocompatibility, the easy conjugation of 
targeting ligands and fluorophores, and the inclusion of steric-
stabilizing agents such as PEG. Due to the twin alkyl chain 
structure of phospholipids, hydrophobic interactions between 
the molecules are increased compared with single-chain CTAB, 
hence phospholipid bilayers are more stable and thus suffer 
significantly less depletion to the surrounding solvent.[39] Phos-
pholipids can be purchased relatively cheaply in bulk (≈0.23 $ g−1) 
and the surfactant exchange procedure is straightforward, scal-
able, and reproducible.
This study focuses entirely on phospholipid exchange proto-
cols, as oleate is too toxic to use for in vivo applications, having 
an intravenous median lethal dose (LD50) of 150 mg kg−1 in mam-
mals (by comparison CTAB is 44 mg kg−1).[45,46] Naturally occurring 
phosphatidylcholines have an LD50 above 10  000 mg kg−1  
and are widely considered nontoxic since they comprise 
20–25% of cell membranes.[47,48]
Phospholipid-functionalized AuNRs were prepared following 
a protocol similar to that published by Matthews et al. for the 
preparation of dioleoylphosphatidylcholine (DOPC) – diole-
oylphosphatidylglycerol (DOPG) functionalized AuNRs, which 
consists of resuspending and sonicating AuNRs in a solution 
containing phospholipid single unilamellar vesicles (SUVs) 
solution.[38] They reported that displacing with DOPC alone 
led to unstable AuNRs,[38] which disagrees with other studies 
utilizing phosphatidylcholines.[39,40,42,49] We found here that 
increasing the sonication time to ≈24 h and undergoing three 
rounds of displacement produced stable DOPC coated AuNRs. 
Consequently, the protocol was also made more reliable when 
scaling up to several hundred milliliters. Also, this protocol 
was found to work with both DOPC and DOPC – DOPG 
(19:1) mixtures. Additionally, it also allows the incorporation 
of PEGylated lipids, for which 95 mol% DOPC with 5 mol% 
distearoylphosphatidylethanolamine-methoxypoly(ethylene 
glycol) (DSPE-mPEG) was used, to provide additional steric sta-
bilization, which produced similarly stable AuNRs.[50]
2. Results and Discussion
2.1. CTAB Replacement by Phospholipids
AuNRs were prepared using a seedless protocol utilizing a 
mixture of oleate and CTAB as stabilizers and shape-directing 
agents (Figure 1).[16] The concentrations of these agents were 
selected to produce AuNRs with a peak localized surface 
plasmon resonance (LSPR) wavelength of 811  nm, which pro-
vides low in vivo attenuation and optimized contrast for photo-
acoustic imaging in the first NIR biological window.[51] UV–vis 
spectra and TEM of the AuNRs are shown in Figure 1a,b, respec-
tively. The mean dimensions of these AuNRs were a length of 
57  nm and a diameter of 13.1  nm, with standard deviations 
of 7 and 1.2 nm, respectively, as determined from the TEM 
















Figure 1. a) Spectra of AuNRs prepared for this study before and after phospholipid displacement. b) TEM image of the as-synthesized AuNRs.
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measurements (Figure S1, Supporting Information). The CTAB 
– oleate coating was exchanged via resuspension in a DOPC 
– DSPE-mPEG (19:1) SUV solution for 24 h under sonication, 
repeated threefold, resulting in a slight blueshift of the LSPR 
to 801  nm with no indication of aggregation in spectrum. No 
change in morphology was observed as result of this exchange 
(Figure S2, Supporting Information). A lower sonication time 
of 4 h resulted in AuNRs which aggregated during centrifuga-
tion, a sonication time of 24 h produced AuNRs which could 
be repeatedly pelleted by centrifugation without loss of the 
AuNRs’ plasmonic properties. After a single cycle of sonica-
tion, the ζ-potential of DOPC AuNRs in 1 mM NaCl (pH 7) was 
measured to be positive (8 ± 4 mV), presumably due to the con-
tinued presence of CTAB (consistent with refs [39,42]). After the 
second cycle of displacement, the ζ-potential was measured to 
be neutral. For biomedical applications, the maximum possible 
reduction of CTAB was a priority and a further round of phos-
pholipid displacement was added to minimize the presence of 
residual CTAB. A sample of this batch was also coated with PSS 
to be used during in vitro and in vivo experiments. These par-
ticles were used for all tissue culture experiments and in vivo 
experiments, these particles were used for all further experi-
ments unless otherwise stated. To assess the molecular spe-
cies, which were present on the surface of the AuNRs after the 
displacement, 1H NMR spectroscopy, surface enhanced Raman 
spectroscopy (SERS), and ζ-potential measurements were used.
2.1.1. 1H Nuclear Magnetic Resonance Spectroscopy
1H NMR spectroscopy was used to directly measure the chemical 
shifts of the ligands bound to the surface of both CTAB – oleate 
AuNRs and DOPC – DSPE-mPEG AuNRs. NMR spectroscopy of 
NP surface coatings is challenging due to both the small amount 
of material adhered to the particle surface and the long rotational 
tumbling time of nanoparticles compared to free molecules.[52] 
These combine to cause decreased signal intensity and broad-
ened spectral peaks, which together to reduce the resolution of 
peaks. However, it is still possible to extract useful information 
about the molecular species present on the surface of the parti-
cles. The obtained spectra for the AuNRs are given in Figure 2  
along with the identified chemical shifts for each functionali-
zation in Tables 1 and 2. The identification of the NMR peaks, 
for each molecule, is given in Section S5, Supporting Informa-
tion. Before spectra collection, AuNRs were washed threefold by 
centrifugation and resuspended in D2O to remove residual free 
lipid and CTAB. The CTAB – oleate AuNRs were kept as a pellet 
after the final centrifugation step and resuspended immediately 
Figure 2. 1H NMR spectra for a) ≈25 nM CTAB – oleate (4:1) AuNRs and b) ≈25 nM DOPC – DSPE-mPEG (19:1) AuNRs. Chemical shift labels are 
given in Table 1. All spectra are taken in D2O, details of sample preparation and acquisition settings for each spectrum are given in Section S5, Sup-
porting Information. Inset in each figure are the molecular structures of a) CTAB and oleate, and b) DOPC and DSPE-mPEG. The spectra of solutions 
containing free CTAB, oleate, DOPC, and DOPG are given in Figure S4, Supporting Information. The grey band indicates the N-methyl protons of the 
trimethylammonium groups of interest.
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before spectra collection to avoid aggregation occurring due to 
CTAB depletion from the AuNR surface.
Figure  2a shows the spectrum obtained for CTAB – oleate 
AuNRs, the presence of CTAB and oleate can be inferred from 
the observed peaks (Figure S5a,b, Supporting Information). In 
particular, the asymmetric peaks at 0.94 and 1.36 ppm correlate 
well with the resonances of the CH3 and [CH2] 1H nuclei 
of the aliphatic chains. Peaks at 2.10 and 5.41  ppm match the 
expected positions for 1H nuclei neighboring and within the 
alkene of the oleate chain, respectively. Shifts from the 1H nuclei 
located in the [CH2] groups closest to the carboxylic acid 
head group of oleate are also visible at 1.62 and 2.18 (weak) ppm. 
Similarly, the protons from the equivalently positioned [CH2] 
groups in CTAB can also be resolved in the spectrum at 1.81 and 
3.39 ppm. A single peak associated with the N-methyl protons of 
CTAB can be observed at 3.20 ppm. These peaks suggest a mixed 
composition of CTAB and oleate present on the AuNR surface.
In the spectrum of the DOPC – DSPE-mPEG AuNRs 
(Figure  2b); peaks at 0.91, 1.31, and 1.60 (weak) ppm can be 
attributed to the aliphatic chains in both DOPC and DSPE-
mPEG. Additionally, peaks at 2.04 and 5.33 (weak) ppm can be 
attributed to the alkenes in the chains of DOPC. The 1H res-
onances of the [CH2] groups in the PEG chains of DSPE-
mPEG are visible at 3.71 ppm. A single peak can be observed 
at 3.27  ppm associated with the N-methyl protons of DOPC. 
Combined these are consistent with a mixed composition of 
DOPC and DSPE-mPEG present on the surface of the AuNRs.
The peaks of the aliphatic chains in CTAB, oleate, and the 
phospholipids broadly overlap. However, the peaks associated 
with the N-methyl protons of the CTAB and DOPC headgroups 
fall at different chemical shifts, 3.20 and 3.27 ppm respectively, 
and can be used as an identifier for the presence of CTAB. 
This difference in chemical shifts has previously been used 
by Orendorff et al. to demonstrate the removal of CTAB from 
the surface of palmitoyloleoylglycerophosphocholine (POPC)-
function alized AuNRs.[39] In the spectrum of the DOPC – DSPE-
mPEG AuNRs, the CTAB N-methyl proton peak (3.20  ppm) 
is not visible, there is instead only a single peak at 3.27 ppm. 
While complete elimination is impossible to conclude from the 
low signal-to-noise ratio of these measurements, they do sug-
gest that substantial displacement of the CTAB from the sur-
face of the AuNRs by phospholipids has occurred. However, 
this measurement on its own is limited and needs to be sup-
ported by additional characterization.
The chemical shift of the N-methyl protons of the AuNR-
bound CTAB is lower than observed in free molecular CTAB 
solutions (Figure S5, Supporting Information). This has been 
reported elsewhere and is caused by a Knight shift due to the 
proximity of the group to the Au surface of the AuNR.[39,53,54] 
The value of 3.20 ppm seen here is also higher than seen for 
Au-bound CTAB elsewhere (i.e., 3.11 ppm,[39] 3.12 ppm,[53] and 
3.16 ppm[54]), it is speculated that this may result from the 
inclusion of the negatively charged headgroup of oleate incor-
porated into the surface-bound CTAB bilayer, such changes in 
the chemical shifts have been observed in mixed micellular sys-
tems.[55] Regardless, it can still be resolved from the observed 
position of the DOPC N-methyl resonance at 3.27 ppm.
2.1.2. Surface-Enhanced Raman Spectroscopy
SERS was also used to identify the molecular species present on 
the surface of the phospholipid functionalized AuNRs. Post-phos-
pholipid exchange AuNRs presented an LSPR peak wavelength of 
801 nm (FWHM = 124 nm) close to the 785 nm wavelength of the 
laser, enabling a large field enhancement for SERS. The obtained 
spectra for the CTAB – oleate AuNRs and DOPC – DSPE-mPEG 
AuNRs are presented in Figure 3a,b, respectively.
To identify residual CTAB, the discussion here shall be 
restricted to the relevant features of the spectra. Firstly, a strong 
background signal can be seen in the spectrum of the DOPC 
– DSPE-mPEG (19:1) AuNRs making the spectrum appear to 
have a very uneven baseline. These originate from the PEG 
chains of DSPE-mPEG. These chains, being further from the 
Au surface, are less enhanced than other molecular groups, 
they comprise a large fraction of the surface coating and thus 
produce the observed background signal. The Raman spectra 
of PEG characteristically have strong bands resulting from 
overlapping peaks in the following regions 770–900, 1015–1170, 
1230–1330, and 1410–1480 cm−1.[56] These bands have been 
marked in Figure  3b, and the various peaks which contribute 
to them are summarized in Table S2, Supporting Information.
The band at 176 cm−1 has been attributed to the Au–Br− 
stretching mode (ν(Au–Br−)) mode.[57] This peak is not pre-
sent in pure CTAB and has been observed elsewhere to shift 
in AuNP solutions when the counter-ion is exchanged with 
other halide ions, such as chloride.[57] The presence of this peak 
Table 1. Chemical shift labels for the CTAB and NaOL AuNR H1 NMR 
spectrum given in Figure 2a.
Label Chem. Shift [ppm] Identification
CTAB Oleate
a 0.94 16 (CH3) 17 (CH3)
b 1.35 3–15 (CH2) 3–6, 11–16 (CH2)
c 1.62 – 2 (CH2)
d 1.81 2 (CH2) –
e 2.10 – 7, 10 (CH2)
f 2.18 – 1 (CH2)
g 3.20 γ (CH3) –
h 3.39 1 (CH2) –
i 5.41 – 8, 9 (CH)
Table 2. Chemical shift labels for the DOPC – DSPE-mPEG AuNR H1 
NMR spectrum given in Figure 2b.
Label Chem. Shift [ppm] Identification
DOPC DSPE-mPEG
a 0.91 17, 17′ (CH3) 17, 17′ (CH3)
b 1.31 3–6, 11–16 (CH2) 3–16 (CH2)
3′–6′, 11′–16′ (CH2) 3′–16′ (CH2)
c 1.60 2, 2′ (CH2) 2, 2′ (CH2)
d 2.04 7, 10, 7′, 10′ (CH2) –
e 3.27 γ (CH3) –
f 3.71 – δn, εn (CH2)
g (5.33) 8, 9, 8′, 9′ (CH) –
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is not unexpected, as bromine forms a relatively strong polar 
covalent bond with the Au surface, and AuBr− can bind to the 
trimethylammonium head groups of both phosphocholine and 
CTA+. This bromide peak is thus expected to continue to be 
present, even after the exchange of the CTA+ and should enable 
the binding of phosphocholines to the Au surface. Indeed, this 
peak has been observed to remain in SERS studies by Mat-
thews et  al. of AuNRs coated by DOPC displacement of the 
CTAB lending further support to this conclusion.[38]
Two bands are of primary interest, firstly at 763 cm−1 in the 
CTAB-oleate AuNR spectrum from the symmetric ν(C4N+) 
mode, used widely as a diagnostic for the presence of CTAB on 
AuNPs (Figure  3a).[38,40,58,59] And secondly that at 720 cm−1 in 
the DOPC – DSPE-mPEG AuNR spectrum associated with the 
symmetric ν(C4N+) mode of the choline headgroup in DOPC 
(Figure  3b). Despite both these modes originating from a tri-
methylammonium group, the proximity of the strongly elec-
tronegative oxygen in the choline of DOPC leads to a lower 
wavenumber peak. The absence of a peak at 768 cm−1 in the 
DOPC-DSPE-mPEG AuNR spectrum implies that the CTAB 
population on the surface of the AuNRs has been reduced 
below the threshold of detection. Whilst it is possible to say that 
the majority of the CTAB has been removed, a lower limit is dif-
ficult to determine by this technique.
2.1.3. ζ-Potential
Finally, to complement the characterization of the AuNR sur-
face coatings, a pH-dependent ζ-potential study was undertaken 
before and after the exchange of the CTAB with phospholipid.
To allow the identification of residual CTAB on the AuNRs, 
a single batch was prepared without the presence of oleate 
(Figure S6, Supporting Information). These CTAB-only AuNRs 
present a positive charge at all pH values (Figure 4a), this is 
consistent with the behavior expected for CTAB. The measured 
value of ζ = (20.4 ± 0.7) mV, reflects the depletion of the surface-
bound CTAB due to repeated washing by centrifugation. The 
surface charge presented by the CTAB coating is dependent 
on the concentration of free CTAB in the suspending medium 
and the dynamic equilibrium between this and surface-bound 
CTAB.[22]
By comparison, AuNRs prepared using a mixture of 38 mM 
CTAB and 12  mM oleate yield a ζ-potential which is pH-
dependent (Figure  4a). The ζ-potential is positive at all pH 
values consistent with a higher surface concentration of CTA+ 
than oleate−. However, the presence of the negatively charged 
oleate ions in the surface coating has substantially suppressed 
the ζ-potential (≈12  mV for pH > 7).  Although the reported 
pKa for a free oleate molecule is 5.0, the surface-bound oleate 
here presents an apparent pKa of 4.3 due to it being packed 
amongst an excess of positively charged trimethylammonium 
headgroups. This leads to localized repulsion of cations in the 
vicinity of the water/bilayer interface and a localized pH shift 
of ≈0.7.[60,61]
AuNRs which have undergone exchange with DOPC also 
show a pH-dependent ζ-potential (Figure 4b). This results from 
the zwitterionic character of DOPC; it is neutrally charged at 
physiological pH and above but presents a positive charge for 
pH values <5. The phosphate group in the free DOPC mole-
cule has a pKa of 1.88, but this shifts to around pH ≈1 when the 
molecule is embedded in a bilayer.[62] The DOPC AuNRs follow 
Figure 3. SERS spectra of AuNRs functionalized with a) CTAB – oleate (3:1), and b) DOPC – DSPE-mPEG (19:1). Peak positions have been annotated 
based on the identifications that are given in Tables S1 and S2, Supporting Information. In (b) strong bands are visible in the spectrum resulting from 
the broad overlapping peaks associated with the PEG chains of DSPE-mPEG. The regions occupied by these bands are marked in grey above the spec-
trum, the specific Stokes shifts contributing to these have been marked on the spectrum itself in grey.
Small 2021, 2006797
2006797 (6 of 12)
www.advancedsciencenews.com
© 2021 The Authors. Small published by Wiley-VCH GmbH
www.small-journal.com
this behavior, but the effective pKa of the AuNR-bound lipids 
cannot be reliably determined, because it requires measure-
ment at a pH where all phosphate groups are protonated (i.e., 
<pH 0), which was not practical to work at. The pH response is 
significantly broadened, which has been observed elsewhere for 
PC lipids bound to nanoparticles.[39]
Notably, the DOPC AuNRs have a ζ-potential of ≈0 mV above 
pH 5 (to within error) consistent with the removal of positively-
charged CTA+ from the AuNR surface. Previously reported 
ζ-potentials for AuNRs functionalized by phosphatidylcho-
lines still display some positive charge at high pH, implying 
the continued presence of CTA+.[39,41,42] Comparatively, neutral 
surface potential (to within ± 3  mV) was observed suggesting 
the additional rounds of sonication in phospholipid SUV solu-
tion deployed here are effective at removing this residual CTAB 
from the surface coating.
Finally, the measurements were repeated on AuNRs coated 
with a 19:1 mixture of DOPC and DSPE-mPEG (Figure  4b). 
Whilst the phosphate groups of DOPC and DSPE-mPEG both 
have pKa values of around 1.8, they should not have an apparent 
effect on the pH response of particles functionalized with a sig-
nificant number of PEGylated phospholipids. Since ζ-potential 
measurements are only sensitive to the functional groups 
exposed at the surface of the particle, the extended PEG brush 
structure should effectively screen the pH response of the 
phosphate and trimethylammonium groups present on these 
molecules. It was therefore expected, based on the protonation 
dynamics of PEG, that the particles would present a neutral 
ζ-potential at all pH. This was not observed, instead, the par-
ticles displayed a slightly negative ζ-potential at low pH, which 
grows increasingly negative with increasing pH, this behavior 
has been observed elsewhere (e.g., refs. [63,64]). This can likely be 
explained by the preferential absorption of anionic species onto 
the PEG, which has been observed to occur for oligo(ethylene 
glycol) monolayers.[65]
The observed shifts in ζ-potential are consistent with 
the known pKa values of the molecules that functionalize 
the AuNRs in this study. The absence of any positive charge 
on the DOPC-functionalized AuNRs implies that the level of 
CTAB on the surface of the AuNRs was successfully reduced 
to trace levels during the phospholipid exchange process 
described above. This was supported by the NMR and Raman 
spectroscopy. In all cases, the presence of CTAB was not 
detectable by any technique in the phospholipid-functional-
ized AuNR samples implying its displacement to near-zero 
levels.
2.2. Stability in Biologically Relevant Media
While stability in biologically relevant media has been assessed 
for more common AuNR coatings such as CTAB and PSS, the 
stability of phospholipid-coated AuNRs outside of the unde-
manding environment of deionized water has received no 
attention.[40,42,48,66] The stability of our AuNRs was explored in 
a variety of “biologically relevant media”, such as buffers, cell 
culture medium (CCM), serum, and plasma. Three buffers 
were selected as surrogates to test the impact of similar ion 
concentrations to those seen in human plasma on the stability 
of AuNPs. Two commercially available buffers were used, Dul-
becco’s phosphate-buffered saline (DPBS) and Plasma-Lyte 148 
(PL-148), an isotonic intravenously administered fluid replace-
ment with physiological pH and balanced electrolyte compo-
nent. These buffers are optimized for cell culture and rapid 
intravenous metabolization, respectively. Thirdly, a bespoke 
buffer was prepared to closely match the homeostatic concen-
trations of the most common electrolytes in human plasma 
(Cion ≥ 1 mM) dubbed “pseudo-plasma” buffer (PP). In addition 
to these electrolyte mixtures, mixtures of RPMI 1640 CCM and 
fetal bovine serum (FBS) were also used. Because FBS is heat-
treated to remove the fibrinogen and coagulant protein content, 
murine plasma containing these proteins was also tested. This 
represents the closest possible match to the in vivo models in 
which these particles will be tested. A detailed breakdown of 
the electrolyte profiles and biomolecule content of these media 
is provided in Section S8, Supporting Information. Aggregation 
is readily seen in the UV–vis spectra as a broadening and shift 
in the peak wavelength of the LSPR bands. Spectra were taken 
Figure 4. Experimentally determined ζ-potentials for AuNRs coated with a) CTAB, & CTAB – oleate (4:1), and b) DOPC, & DOPC – DSPE-mPEG (19:1) 
as a function of buffer pH (Cion = 10 mM).
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over 2 weeks, presented in their entirety in Section S8.1–S8.7, 
Supporting Information, a few selected examples are presented 
in Figure 5.
The stability of CTAB AuNRs was assessed by two parallel 
experiments. AuNRs were washed threefold and suspended 
in the media of interest and additionally with the same media 
including an additional 1  mM CTAB. This made it possible 
to distinguish between aggregation induced by the degrada-
tion of the CTAB bilayer and charge screening due to ions in 
solution. The effect of this was easily visible in the results, 
DPBS, PL148, and PP buffers containing washed CTAB AuNRs 
show aggregation at 96, 197, and 188 mOsmL−1 respectively. 
When 1 mM CTAB was included alongside the particles, these 
concentrations at which they became unstable increased to 
193, 197, and 282 mOsmL−1 respectively. CTAB AuNRs were 
unstable in all CCM + FBS combinations, but the presence 
of 1  mM CTAB significantly increased their stability. CTAB 
appears to be a poor stabilization agent under biological con-
ditions, although this is somewhat immaterial given its high 
cytotoxicity.
PSS is often considered a good moiety with which to pro-
vide strong charge stabilization to AuNPs.[67,68] However, 
here PSS AuNRs were observed to aggregate at 289, 198, and 
94 mOsmL−1 in DPBS, PL148, and PP, respectively. Faster and 
more complete aggregation was observed above these concen-
trations. PSS-coated AuNRs were also unstable in CCM. This 
Figure 5. Absorbance spectra of AuNRs during stability testing over 2 weeks. a–c) CTAB – oleate, d–f) PSS, and g–i) DOPC – DSPE-mPEG functional-
ized AuNRs in (a,d,g) DPBS, (b,e,h) RPMI 1640 cell culture media, and (c,f,i) mouse plasma. The top section of each panel shows a series of UV–vis 
spectra of each experimental condition at different time points over 2 weeks. The lower panel shows the magnitude of the LSPR (normalized to t = 0) 
as a function of time. A full summary of the stability data under all conditions is given in Section S8, Supporting Information.
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has been observed previously, where the presence of serum 
proteins was required to maintain stability.[69] The particles 
here were not stable in 10% FBS-enriched CCM, however other 
studies have observed PSS AuNRs to be stable under these con-
ditions (i.e., refs. [12,69]). Increasing the serum content further 
did provide stability and PSS-functionalized AuNRs show good 
stability in 50% and 100% serum, suggesting corona formation 
can stabilize the particles, consistent with these other results.
The PSS AuNRs aggregate at a faster rate than CTAB – oleate 
AuNRs in mouse plasma. Throughout the experiment the 
LSPR decreased to the point of being virtually undetectable, 
accompanied by an increase in the extinction at higher wave-
lengths consistent with the formation of aggregates.
No aggregation was visible in the spectra of DOPC – DSPE-
mPEG in any of the buffers, in CCM, or in serum. The optical 
properties were consistent across all concentrations and time 
points. Some aggregation was observed in mouse plasma. The 
intensity of the LSPR is around 80% of its initial value after 24 h, 
which is still high enough to be utilized for photothermal 
therapy, suggesting they are stable enough for in vivo appli-
cation. DOPC – DSPE-mPEG AuNRs outperformed CTAB – 
oleate and PSS AuNRs in all buffers, CCM + FBS combina-
tions, and mouse plasma. This improved stability results from 
the zwitterionic character of DOPC and the additional steric 
stabilization from the PEG chains of DSPE-mPEG. Both stabi-
lization mechanisms do not rely on electrostatic repulsion and 
hence are significantly better at maintaining NP stability under 
highly saline conditions.
All coatings performed considerably worse in mouse plasma 
compared with FBS, likely resulting from non-specific interac-
tions between the AuNRs and the fibrinogen/coagulant pro-
teins absent in FBS. If it is the presence of fibrinogen and 
coagulant proteins that are the cause of this increased insta-
bility, it could have important implications for the applications 
of nanoparticles in vivo and may warrant further investigation.
2.3. In Vitro Studies
To ensure that the particles were not inherently toxic to mam-
malian cells after CTAB displacement, and therefore suitable 
for in vivo use; the cytotoxicity of the DOPC – DSPE-mPEG 
AuNRs was assessed on four cell lines; SW620 human colo-
rectal adenocarcinoma, HEK293 human embryonic kidney, 
HCT116 human colorectal adenocarcinoma, and LS174T colo-
rectal adenocarcinoma. Viabilities were compared against those 
seen for PSS AuNRs, a commonly used biocompatible surface 
functionalization.[12,29,69,70]
The results of the cell viability assays are presented in Figure 6a,b. 
In all cases, the cell incubated with DOPC – DSPE-mPEG AuNRs 
showed higher cell viabilities than their PSS-coated equivalents 
after 24 h co-incubation. For three cell lines, SW620, HCT116, 
and LS174T, ≈100% cell viability was seen even at the highest dose 
administered of 200 µg mL−1. HEK293 cells showed some toxicity, 
reaching 50% viability at (55 ± 1) µg mL−1, by comparison when 
treated with PSS AuNRs this viability was found for dose levels 
over 10× higher (4 ± 1) µg mL−1. The half maximal inhibitory con-
centration (IC50) for the SW620, HCT116, and LS174T cells treated 
with PSS-AuNRs were (102 ± 1), (186 ± 1), and (81 ± 1) µg mL−1, 
respectively.
Previous studies of the cytotoxicity of phospholipid AuNRs 
are limited to two papers. The first in HeLa cells used phos-
phatidylcholine-functionalized AuNRs up to concentrations of 
2.9 µg mL−1 and reported 20% cell death (which seems likely 
to be due to high residual levels of CTAB).[41] The second 
using dimyristoylglycerophosphocholine (DMPC)-functionalized 
AuNRs measured cell viabilities up to 20 µg mL−1 in MCF-7 and 
HMEC-1 cells, with no drop off in viability.[40] These are both 
significantly below the doses presented here. From our results, 
the IC50 has been determined to be over 200 µg mL−1, for the 
three cell lines studied here, this is an excessively high dose 
compared with the concentrations likely to be achieved in vivo.
To demonstrate that this low toxicity did not originate from 
minimal levels of cellular uptake, cells treated with the parti-
cles were studied by optical and electron microscopy. An optical 
darkfield image of cells incubated with 40 µg mL−1 AuNRs for 
6 h is presented in Figure  6c. Large numbers of AuNRs can 
be observed as bright spots within the interior of the cells. The 
number and intensity of these spots were observed to corre-
late strongly with the dose of AuNRs administered (see addi-
tional darkfield images in Section S9, Supporting Information). 
TEM of cell sections shows that the AuNRs were intracellular 
(Figure  6d). Based on cell staining, it appears that these par-
ticles are contained within endosomes, consistent with the 
expected endocytotic uptake route of most nanomaterials.[71] 
These particles appear to be highly biocompatible at the con-
centrations expected to be achieved in vivo.
Another concern relating to the use of nanoparticles in 
vivo is that of hemolysis, the rupture or destruction of red 
blood cells. This is a particular concern for AuNPs func-
tionalized with a positively charged amphiphile such as 
CTAB, which can disrupt cellular membranes.[19] CTAB, 
PSS, and DOPC – DSPE-mPEG AuNRs were assessed for 
their potential to cause hemolysis. The results of this assay 
are shown in Figure 7a. CTAB AuNRs showed high levels of 
lysis at both 100 µg and 20 µg mL−1 (73% and 37% respec-
tively). Additionally, the supernatant (SN) extracted from the 
100 µg mL−1 CTAB sample showed similar levels of lysis 
(41%) to that of the 20 µg mL−1 sample. This is consistent 
with the membrane disruption expected from dissociated 
CTAB in solution.[19,20]
By comparison, the lysed fraction following exposure to the 
SN from both the PSS- and DOPC – DSPE-mPEG AuNRs was 
low (1% and 2% respectively). Similarly, at a concentration of 
20 µg mL−1, low levels of lysis were seen for both the PSS- 
(3%) and DOPC – DSPE-mPEG AuNRs (2%). However, DOPC 
– DSPE-mPEG AuNRs performed better at 100 µg mL−1 with 
a lysed fraction of 8%, compared to the 24% seen using PSS 
AuNRs at the same concentration.
The photothermal heat generation of these AuNRs was 
measured at a range of concentrations and continuous wave 
(CW) laser fluences were measured (Figure S9, Supporting 
Information). The AuNRs synthesized here have a molar 
extinction coefficient of 5.4 × 109 M−1 cm−1 at 811  nm and 
are therefore extremely efficient photothermal conversion 
agents. A local temperature increase above body temperature 
of ≈10 °C is required to achieve cell death over short exposure 
times.[5] This temperature increase was achieved at concen-
trations >50 µg mL−1 at 0.32 W cm−2 (Figure S9a, Supporting 
Information). This fluence is notable as it represents the 
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maximum permissible exposure (MPE) at 811  nm as stated 
by ANSI standard.[72] Utilizing fluences above the MPE, 
temperature increases of 10, 23, and 58 °C, at 1, 2, and 
3 W cm−2 respectively, were achieved at concentrations as low 
as 5 µg mL−1 (Figure S9c–f, Supporting Information). Hence 
these particles are demonstrably suitable for application as 
photothermal conversion agents.
The photothermal stability of the AuNRs was also assessed by 
extended exposure to a CW laser source, which is also a poten-
tial issue due to the possibility of particle reshaping. The parti-
cles showed no discernible change in the extinction spectrum 
and heat generation after a single 10 min exposure at 3 W cm−2 
(Figure S11a, Supporting Information). The AuNRs were quite 
resilient over repeated exposure cycles (a single cycle being 
10  min at 3 W cm−2 followed by 20  min at 0 W cm−2). After 
60 cycles (6 h cumulative exposure), the maximum tempera-
ture generated only dropped by ≈4%. This is a relatively small 
drop and well beyond any exposure time that would be encoun-
tered during treatment, consequently, these AuNRs should be 
well suited to therapeutic applications using CW light sources 
(Figure S11b,c, Supporting Information). At the termination of 
the experiment (160 cycles, >26  h cumulative exposure) this 
had dropped by 25% (Figure S11d, Supporting Information). 
The changes observed here are consistent with the thermal 
reshaping observed in heated solutions of AuNRs.[73,74,75] At the 
maximum temperatures seen here (≈70 °C), these reshaping 
processes occur over hours and should not affect photothermal 
therapy using such particles.
To demonstrate the efficacy of this temperature increase in 
killing cancerous cells, the particles were incubated with SW620 
colorectal adenocarcinoma cells at 20 µg mL−1 for 4 h and sub-
sequently exposed to an intensity of 1 W cm−2, at 801  nm for 
a range of exposure times. Cell viability was reduced to ≈30% 
after 2.5  min and near-complete cell death was observed after 
5 min (Figure 7b). Cell exposure to the laser in the absence of 
AuNRs resulted in no drop in viability.
2.4. In Vivo Studies
Following on from the in vitro studies, murine models were 
used to assess the in vivo toxicity and biodistribution of our 
AuNRs. Immediately following intravenous injection there 
were no visible signs of distress or irritation and no weight loss 
or abnormal behaviors were observed during the following 9 d 
in any of the animals. All mice survived post-injection to the 
planned time of sacrifice. This further supports the conclusion 
that these particles demonstrate good biocompatibility, and are 
well tolerated in the murine model, in agreement with the in 
vitro experiments above.
Figure 6. In vitro cell viabilities of SW620, HEK293, HCT116, and LS174T cells after 24 h incubation with AuNRs. Cells incubated with increasing 
concentrations of a) PSS-AuNRs and b) DOPC – DSPE-mPEG (19:1) AuNRs. Results are expressed as a percentage of the control plates (0 µg mL−1) 
and are the mean result from three plates at different passage numbers. Results are fitted with a Hill-type dose–response curve. From these fits the 
IC50 of the PSS AuNRs are determined to be (102 ± 1), (4 ± 1), (186 ± 1), and (81 ± 1) µg mL−1 for the SW620, HEK293, HCT116, and LS174T cell lines, 
respectively. The DOPC – DSPE-mPEG AuNRs show ≈100% cell viability at all concentrations measured in the SW620, HCT116, and LS174T cell-lines, 
so no IC50 is determined. For HEK293 cells it is determined to be (55 ± 1) µg mL−1 significantly better than the equivalent test with PSS AuNRs. 
c) Darkfield microscopy image of SW620 cells incubated with 40 µg mL−1 DOPC – DSPE-mPEG (19:1) AuNRs for 6 h before fixing. d) TEM image of 
a section through an SW620 cell incubated for 4 h before fixing. AuNRs can be seen to have been taken up into endosomes as denoted by the darker 
circular structures shown in the magnified inserts.
Small 2021, 2006797
2006797 (10 of 12)
www.advancedsciencenews.com
© 2021 The Authors. Small published by Wiley-VCH GmbH
www.small-journal.com
Biodistribution studies were undertaken to determine the in 
vivo fate of the phospholipid AuNRs in tumor-bearing mice. This 
was achieved by ex vivo inductively coupled plasma mass spec-
trometry (ICP-MS) analysis of the organs of the injected mice har-
vested 1, 2, and 9 d post-injection. It was expected that the tissues 
which would show the highest uptake were the liver and spleen 
due to clearance by the mononuclear phagocyte system (MPS), 
and elimination via the hepatobiliary route.[76] The results of this 
study expressed as a fraction of the injected dose (%ID) are pre-
sented in Figure  7b. Most of the sample was found in the liver 
(≈15%), however, when the mass of the digested tissue (%ID per 
gram of tissue, %IDg−1) is accounted for, the density of Au within 
the spleen is similar to that seen within the liver (Figure 7c). This 
distribution is consistent with reported biodistribution values for 
PEGylated particles more generally.[77–80]
The concentrations of these particles in the liver and spleen 
can be seen to decrease with time, likely due to the particles being 
cleared by the MPS. Au was still detectable in the liver and spleen 
after 9 d, paired with the observation of relatively low quantities of 
Au in the colonic feces, suggesting a relatively low rate of elimi-
nation. Further experiments are required to fully characterize the 
timescale over which these particles are eliminated by the body. 
Although some studies of PEGylated particles have detected par-
ticles in the liver and spleen 15 months after the administration 
of the original AuNPs, indicating that complete elimination may 
never be achieved.[81] However, in most cases, there are no reports 
of long-term toxicity emerging from this continued presence. It 
remains an open question whether the persistence of such parti-
cles in vivo should be tolerated as part of any treatment.
Only a very small proportion of the injected dose was 
observed in the subcutaneous tumor ((0.4 ± 0.2)%, (0.1 ± 0.03)%, 
and (0.1  ± 0.08)% at 1 d, 2 d, and 9 d, respectively), therefore 
the particles did not preferentially accumulate here, or any 
accumulation occurred over a different timescale compared to 
the chosen time points. Modification of the particles with active 
targeting could potentially increase the uptake of these particles 
within the tumor especially with the recent finding by Sind-
hwani et al. that 97% of AuNP entry to tumors is via an active 
rather than passive mechanism.[82]
No residual Au is seen in any of the other organs, the %ID 
measured for the brain, colon, heart, kidneys, lungs, sex organs, 
and skin are all close to the detection limit for our samples in 
the ICP-MS. This is expected but also indicates that DOPC – 
DSPE-mPEG functionalized AuNRs are not being retained 
because of some unknown interaction resulting from the sur-
face functionalization in any of the other major organs.
3. Conclusion
This work demonstrates that the displacement of CTAB 
with a variety of phospholipids can be achieved through 
repeated rounds of sonication and cleaning through centrif-
ugation. This repeated process appears to be more effective 
at removing CTAB from the surface of AuNRs than other 
published methods, producing no detectable CTAB when 
characterized by NMR spectroscopy, SERS, and ζ potential 
measurements.
Figure 7. a) Measured hemolysis fractions for DOPC – DSPE-mPEG, PSS, and CTAB -oleate AuNRs at 100 µg and 20 µg mL−1. The lysis values for 
the supernatant (SN) extracted from a 100 µg mL−1 samples are also presented. b) Viabilities of SW620 cells exposed to 1 W cm−2 CW light. Cells are 
incubated with 20 µg mL−1 DOPC – DSPE-mPEG AuNRs for 4 h before illumination. Cell viability assays are repeated in triplicate and are expressed 
as a percentage of the control viability (no Au, no laser exposure). c) Measured Au concentrations in mice treated with DOPC – DSPE-mPEG AuNRs 
in each of the tested tissues expressed as a percentage of the injected dose (%ID). d) The same %ID values expressed per gram of dry tissue sample 
(%IDg−1). Note: a larger vertical scale has been used for the liver and spleen to that of all other organs.
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Furthermore, these particles present superior stability com-
pared with the other surface functionalizations tested here in a 
variety of biologically relevant media. In vitro models showed 
very high levels of biocompatibility and are well tolerated by 
murine models when administered in vivo. They have high 
photothermal conversion efficiencies, achieving high tempera-
tures when illuminated by NIR light that are capable of rap-
idly inducing cell death in cancerous cells. They do, however, 
appear to have a relatively low rate of clearance from the liver 
and spleen, which warrants further investigation over a longer 
timescale.
Thus, phospholipid coated AuNRs represent a promising 
avenue for further cancer nanomedicine research and should 
be highly effective in applications such as plasmonic photo-
thermal therapy and photoacoustic imaging. The method pre-
sented here is highly robust and can be utilized with a wide 
range of phospholipids, enabling highly tailorable surface 
properties to be achieved in a straightforward and cost-effective 
protocol.
4. Experimental Section
Details of the materials used, and experimental methods can be found 
in the Supporting Information (Sections S1 and S2, respectively). All 
animal procedures were approved by the UK Home Office and carried 
out according to the Animals (Scientific Procedures) Act 1986 and 
under the project license of Dr. P. Louise Coletta (70/7965) with all work 
involving the handling of live animals was performed by Dr. Nicola 
Ingram under PIL IDD6965FF.
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